Validation Testing of Accelerator Mass Spectrometry Plutonium Bioassay Measurements Conducted at the Lawrence Livermore National Laboratory

T.F. Hamilton
T.A. Brown
A.A. Marchetti
G.F. Payne
R.E. Martinelli
S.R. Kehl
R.G. Langston
J.M. Rankin

50th Annual Conference on Bioassay, Analytical and Environmental Radiochemistry, Cincinnati, OH, USA (October 30-November 3, 2005)

September 2005
This document was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor the University of California nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or the University of California. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or the University of California, and shall not be used for advertising or product endorsement purposes.

This work was performed under the auspices of the U.S. Department of Energy by the University of California, Lawrence Livermore National Laboratory under Contract W-7405-Eng-48.
The Lawrence Livermore National Laboratory (LLNL) has recently developed an accelerator mass spectrometry (AMS) measurement system designed specifically for low sensitivity, high sample throughput, and robust measurements of actinide elements. The aim of this AMS research and development effort was to improve upon the existing bioassay measurement technologies being used to assess occupational, military, and public exposures to plutonium isotopes. Specifically, the newly developed AMS measurement system offers a number of potential operational and technological advantages for radiation protection programs compared to the more classical bioassay detection technologies that are based on alpha-spectrometry or competing newer measurement technologies such as fission track analysis. The U.S. National Institute of Technology and Standards (NIST) have independently verified the accuracy and reliability of the AMS system at LLNL for low-level plutonium bioassay measurements. In fact, results of plutonium-239 ($^{239}$Pu) and plutonium-240 ($^{240}$Pu) measurements in spiked, synthetic-urine samples met ANSI 13.30 criteria for both precision and accuracy at all test levels. Currently, this new measurement technology is being used to improve on the quality and reliability of plutonium exposure assessments in the Marshall Islands, as well as to verify potential workplace intakes of plutonium at LLNL. The AMS measurement technique is continuously tested and verified by analysis of quality-control (QC) samples prepared by researchers from the Oak Ridge National Laboratory (ORNL). These external quality-control samples were prepared as spike additions to aliquots of human urine collected from a low-background donor. The QC samples are normally offered with a declared $^{239}$Pu concentration range of between 30 to 200 $\mu$Bq per sample, and a $^{240}$Pu/$^{239}$Pu atom ratio that approximates that observed in integrated worldwide-fallout deposition, i.e., ~0.2. Based on ANSI 13.30 criteria, the combined measurement bias and precision of the analysis over the duration of the program has been ~0.8% and 5.3%, respectively, for $^{239}$Pu; and +5.2% and 10.7%, respectively, for $^{240}$Pu. Under routine operating conditions the AMS system background is equivalent to about ~1 $\mu$Bq of $^{239}$Pu and ~3 $\mu$Bq of $^{240}$Pu, far exceeding the requirements of the latest U.S. Department of Energy (DOE) regulation stated in 10 CFR 835 for in-vitro bioassay monitoring of plutonium isotopes. Based on these externally validated results and the operational experience of researchers at the LLNL Center for Accelerator Mass Spectrometry (CAMS), the AMS measurement system at LLNL is considered to be the cutting edge technology for the stated purpose, and vastly improves on the capabilities essential for monitoring compliance with the standards for occupational safety and risk management at LLNL, and elsewhere in the DOE complex.